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Abstract Alternatives to the use of fetal bovine serum
(FBS) have been investigated to ensure xeno-free growth
condition. In this study we evaluated the efficacy of
human platelet lysate (PL) as a substitute of FBS for the
invitro cultureof somehumancell lines. PLwasobtained
by pools of pathogen inactivated human donor platelet
(PLT) concentrates. Human leukemia cell lines (KG-1,
K562, JURKAT, HL-60) and epithelial tumor cell lines
(HeLa andMCF-7) were cultured with either FBS or PL.
Changes in cell proliferation, viability, morphology,
surface markers and cell cycle were evaluated for each
cell line. Functional characteristics were analysed by
drug sensitivity test and cytotoxicity assay. Our results
demonstrated that PL can support growth and expansion
of all cell lines, although the cells cultured in presence of
PL experienced a less massive proliferation compared to
those grown with FBS. We found a comparable
percentage of viable specific marker-expressing cells in
both conditions, confirming lineage fidelity in all
cultures. Functionality assays showed that cells in both
FBS- and PL-supported culturesmaintained their normal
responsiveness to adriamycin and NK cell-mediated
lysis. Our findings indicate that PL is a feasible serum
substitute for supporting growth and propagation of
haematopoietic and epithelial cell lines with many
advantages from a perspective of process standardiza-
tion, ethicality and product safety.
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Introduction
In vitro culture of mammalian cells is one of the most
important process in research and drug development.
Expansion of human cells in vitro requires specific
culture conditions and culture media providing growth
factors, proteins and enzymes for cell metabolism,
growth and proliferation. Fetal bovine serum (FBS) is
the most widely used source of nutrients and growth
factors for cell culture (Honn et al. 1975). However,
there are several ethical, scientific and safety problems
with the use of FBS for in vitro cell culture. The use of
FBS raises animal welfare concerns regarding the
harvest procedure for its production. Moreover, there
is an high variability frombatch-to batch that can lead to
inconsistent cell culture performance and may interfere
with the reproducibility of experiments (Jochems et al.
2002). Most importantly, FBS is an animal-derived
component which raises severe concerns for any in vitro
or ex vivo technique aimed at cell growth and propaga-
tion, due to the risk of xenogenic immune reactions
against bovine antigens and transmission of animal
pathogens such as viruses and prions (Gstraunthaler
2003; Sundin et al. 2007). To date, various human-
derived supplements have been tested as an alternative
to FBS, including growth factors, autologous and
allogeneic serum, human plasma and platelet deriva-
tives, such as platelet lysate (PL) and released factors
(Ferro et al. 2012; Gstraunthaler 2003; Hankey et al.
2001; Kocaoemer et al. 2007; Lin et al. 2005;Morimoto
et al. 2011; Stute et al. 2004). Platelets (PLTs) are known
to play many important roles in haemostasis, tissue
repair and wound healing, through their adhesive and
secretory properties (Barsotti et al. 2013).
Additionally, PLTs are a very rich source of
cytokines, chemokines and growth factors, such as
platelet-derived growth factor (PDGF), epidermal
growth factor (EGF), basic fibroblast growth factor
(FGF-b), transforming growth factor-b (TGF-b),
hepatocyte growth factor (HGF), insulin-like growth
factor-1 (IGF-1), and vascular endothelial growth
factor (VEGF), as well as enzymes and attachment
factors (fibronectin and vitronectin) (Reed 2004;
Schallmoser and Strunk 2013). PLTs can be lysed to
release growth factors by a simple freeze–thaw
procedure. Recently, our group developed a protocol
for the production of a standardized and safe PL for
clinical-grade expansion of bone marrow mesenchy-
mal stem cells (MSCs) (Iudicone et al. 2014).
Moreover, several reports have already demon-
strated successful use of human PL as a replacement
for FBS in cell culture. In particular, many studies
have been conducted to develop standardized proto-
cols, in compliance with goodmanufacturing practices
(GMP), to promote growth and proliferation of MSC
without altering their phenotypic and functional
characteristics (Avanzini et al. 2009; Bernardo et al.
2007; Bieback et al. 2009; Castiglia et al. 2014;
Cholewa et al. 2011; Doucet et al. 2005; Fekete et al.
2012; Hemeda et al. 2014; Schallmoser et al. 2007;
Trojahn Kolle et al. 2013; Warnke et al. 2013).
Furthermore, various human cell populations, in-
cluding mesenchymal and epithelial cells (from cord
blood, adipose tissue, bone marrow and peripheral
blood), monocytes, endothelial cells, keratinocytes,
tumor cells, chondrocytes, hepatocytes and fibroblasts
have been used to test the growth-stimulatory effects of
platelet derived growth factors in vitro (Baik et al. 2014;
Barsotti et al. 2013; Bernardi et al. 2013; Hofbauer et al.
2014). Indeed, in 2003, Johansson et al. demonstrated
that PL can fully replace FBS as a culture supplement
both for suspension as well as anchorage-dependent
cells (Johansson et al. 2003). Additionally, experiments
on renal epithelial cells and human leukemia cell lines
showed that the growth promoting effect of 5 % PL is
almost identical compared to that of 10 % FBS (Rauch
et al. 2011). Recently, Schallmoser and Strunk’s results
confirmed that human PL is highly efficient for the
culture of human mesenchymal progenitors and en-
dothelial colony-forming progenitors even when used
at 5 % concentration (Schallmoser and Strunk
2013).Therefore, PL is also expected to be used as a
FBS substitute in human cell lines expansion. In the
present study, PL and FBS were compared in terms of
their abilities to support the normal rate of growth and
expansion of established haematopoietic and epithelial
cancer cell lines for research purposes.
Materials and methods
Human platelet lysate (PL) preparation
PLs were prepared using PLT pathogen inactivated
pools as previously described (Iudicone et al. 2014).
Briefly, whole blood was collected from voluntary
donors selected following current criteria for blood
donation. Buffy-coats (BCs) were obtained by
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centrifugation of whole blood donations according to
the procedures validated in the routine separation of
blood components for transfusion therapy. Six BC-PLT
units were pooled within 24 h from collection and, after
inactivation by the Intercept technology (Intercept
Blood System for Platelets, Cerus Corporation, Con-
cord, CA, USA), were resuspended in InterSol solution
(additive solution, AS; Fenwall Inc., Lake Zurich, IL,
USA) with a 20–30 % residual human plasma in a
volume of approximately 300 mL and a PLT content
ranging from 2.5 to 3.5 9 1011. Two pools of six
pathogen inactivated PLT (PI-PLT) units were connect-
ed each other under sterile conditions to obtain a pool of
12 PI-PLT units, with a PLT count greater than or equal
to 1 9 109 per mL. The final pooled-PLT product was
frozen at -80 C and thawed at 37 C for three
consecutive cycles to lyse PLTs, then centrifuged to
remove PLT membranes and finally aliquoted and
cryopreserved at -80 C until use. Sterility tests were
performed prior and after the entire procedure of PL
production to exclude aerobic, anaerobic and fungal
contamination (BACTEC 9240, Beckton Dickinson,
San Jose`, CA, USA). Several lots of PL were produced
according to the above mentioned protocol and three
lots named PL16, PL17, PL18 were specifically tested
for their capacity to support established tumor cell lines
of different tissue origin.
PL content of PLT derived growth factors
The concentration of PLT derived soluble growth
factors, i.e. PDGF-AB, VEGF, FGF-b and TGF-b was
evaluated in each PL lot by using commercially
available immunoenzymatic kits, (Quantikine Human
PDGF-AB, Quantikine Human VEGF, Quantikine
Human FGF-b, Quantikine Human TGF-b 1, R&D
Systems, Minneapolis, MN, USA) following manufac-
turer’s instructions.
Cell line growth
The following human cell lines were purchased from
American Type Culture Collection (Manassas, VA,
USA): HL-60 (acute promyelocytic leukemia), KG-1a
(acute myelogenous leukemia), Jurkat (T cell leukemia),
K562 (chronicmyelogeneous leukaemia),MCF-7 (breast
adenocarcinoma), HeLa (cervix adenocarcinoma). KG-
1a andHL-60 cellswere seeded at 500.000 cell per ml in
Iscove’s Modified Dulbecco’s Medium (IMDM; Lonza,
Walkersville, MD, USA) supplemented with 20 % FBS
(Euroclone, Pero,MI, Italy) or 20 %PL. Jurkat andK562
cells were seeded at 500.000 cell per ml in RPMI 1640
medium (Lonza, Basel, Switzerland) supplemented with
10 % FBS or 10 % PL and 2 mM L-glutamine (Euro-
clone). Culture medium was replaced every 3 or 4 days.
HeLa and MCF-7 cells were cultured in adherence at
10.000 cell per cm2 in Dulbecco’s Modified Eagle
Medium (DMEM) high glucose (Lonza) additioned with
10 % FBS or 10 % PL. Medium was renewed twice a
week and when the cells reached confluence, usually
within 1 week, they were detached by Trypsin–EDTA
treatment (Euroclone) for counting and then re-seeded at
appropriate concentration for next propagation steps.Cell
enumeration at each passage was performed by flow
cytometry analysis to identify lineage specific cells using
the following monoclonal antibodies (Mo-Ab): CD235a
FITC for K562 (Dako Denmark, Glostrup, Denmark),
CD33 PE for HL60 (Miltenyi Biotech GmbH, Bergisch
Gladbach, Germany), CD3 FITC for Jurkat, CD34 PE
and CD45 FITC for KG-1a, CD146 PE for HeLa, CD29
PE for MCF-7 cells (Becton-Dickinson, San Jose´, CA,
USA). Briefly, a known volume of each cell line culture
was incubated150 in the darkwith the appropriateMo-Ab
and 7-AAD (7-amino-actinomycin D) (Becton–Dickin-
son) to exclude dead cells. At the end of incubation, pre-
defined amounts of fluorescent beads were added to the
stained cells and beads were counted along with cells by
using aFacsCalibur (Becton–Dickinson) todetermine the
absolute cell number per ll. Cellswere gated on the basis
of their physical features, forward and side scatter signals,
and fluorescent signals. Two counts were performed for
each sample and the average value of replicates was
accepted as the correct absolute cell number. Doubling -
time was calculated at every passage and the expansion
rate was determined by dividing the total number of cells
counted by the number of cells initially seeded. The three
PL lots, PL-16, PL-17 and PL-18, were tested in parallel
with FBS to evaluate the ability of each PL preparation to
sustain the growth of the cell lines. To this aim, each cell
line underwent six passages and the experiments were
replicated three times. Prior to their use in growth
experiments, each PL lot, including those tested in the
present study, were subjected to a bone marrow-derived
MSC-based ‘‘potency test’’ to verify that MSC conflu-
enceoccurredwithin15 days at the initial culture passage
(P0) and that a minimum threefold expansion was
documented at any further culture passage (P1, P2, P3
etc.). Similarly, the concentration of more biologically
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relevant growth factorswere assessed as described above,
to assure that each usable PL lot had concentrations not
lower than the 70 %of themean concentrations observed
in 20 consecutive PL previous lots (see also Fig. 1).
Cell cycle analysis
Cells obtained from each cell line culture were
harvested and washed twice with PBS with 2 mmM
EDTA (Sigma-Aldrich; St. Louis, MO, USA). Sam-
ples were incubated for 30 min at room temperature
with a hypotonic DNA staining Solution containing
50 lg/ml Propidium Iodide (Becton–Dickinson),
6.25 lg/ml RNase A (Qiagen Inc., Valencia CA,
USA) and 12.5 ll/ml Nonidet P40 (Sigma-Aldrich; St.
Louis, MO, USA). Samples were run on a FacsCalibur
(Becton–Dickinson) and analysed with ModFit LT 4.0
(Verity Software House, Inc., Topsham, ME, USA).
Chemosensitivity test
To measure the sensitivity to adriamycin, Jurkat, KG-
1a and HL-60 cells were seeded in duplicate in culture
media with or without adriamycin (Menarini, Flor-
ence, Italy) (concentration range 0.5–0.0025 lg/ml).
Cells were counted 72 h after seeding by flow
cytometry analysis and expressed as absolute count
as described in the previous section.
Cytotoxic assay
The lytic activity of IL-2 activated CD56? effector
cells against K562 target cells, cultured with FBS or
PL17 or PL18, was evaluated by carboxy fluorescein
diacetate succinimidyl ester [CSFE ( Life Technology,
Carlsbad, CA, USA )] based cytotoxic assay. Periph-
eral blood mononuclear cells (PBMC), obtained from
healthy donors after written informed consent, were
separated by density gradient Lympholyte (Cedarlain
Laboratories, Ontario, Canada), centrifuged and cul-
tured at 2 9 106 cells per ml in RPMI (Lonza) sup-
plemented with 10 % FBS, L-Glutamine, antibiotics
and IL-2 1000 U/mL (Miltenyi Biotech GmbH). On
day 7, the lymphocyte subsets (CD3, CD4, CD8,
CD45, CD16, CD56, CD19) were evaluated by
Immunomonitoring Kit (Becton–Dickinson) and the
CD56? cells, both CD3?CD56? and CD3-CD56?,
were used as effector cells in the cytotoxic assay.
10 9 106 K562 target cells were labeled with 2 lM
CFSE 100 at 37 C in the dark. Quench staining was
performed on ice for 50 by adding 5 volumes of ice-
cold phosphate buffered saline (PBS) supplemented
with 5 % human albumin (HA) (Grifols, Sant Cugat
del Valles, BCN, Spain). Cells were then washed three
times with cold PBS supplemented with 5 % HA and
re-suspended at appropriate concentration in serum
free medium (X-vivo 10, Lonza). CD56? effector cells
were added to viable labeled target cells at the
following effector/target (E/T) ratios 20:1, 10:1, 5:1,
2, 5:1 and co-cultured for 900. 7-AAD was then added
to mark target dead cells and viable cells were
evaluated by flow cytometry. The percentage of
specific lysis was calculated as % of viable targets
according to the following formula:
% background viable targets  % viable targets
% background viable targets
 100
Fig. 1 Analysis of growth
factor concentration by
ELISA in PL preparations.
Growth factor
concentrations in PL 16, 17
and 18 were compared to the
average concentrations
(mean) observed in 20
consecutive previous PL lots
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Statistical analysis
Data obtained by parallel growth experiments using
FBS and PL16, PL17 and PL18 were compared during
culture passages in terms of doubling time, fold
expansions and sensitivity to adriamycin by a paired
two-tailed Student’s t test. A p\ 0.05 was considered
significant.
Results and discussion
Characterization of platelet lysate
Several lots of PL were produced following a previ-
ously described GMP-compliant procedure (Iudicone
et al. 2014). In our protocol PL lots were obtained by
pooling 12 PLT units following a transfusional-based
procedure, including pathogen inactivation by
Intercept technology and three cycles of freezing and
thawing, followed by membrane removal. This PL
preparation can be considered a safe and well-
standardized human supplement, that can be used as
FBS substitute to support MSCs clinical-scale cultures
without affecting their antigenic and functional prop-
erties. Moreover, we adopted the ability of PL to
sustain MSC growth as a ‘‘potency test’’ to better
characterize, beside the PL growth factor content, the
quality and the potential of our PL preparations. The
efficacy of PL to support in vitro cell proliferation
relies on the content of growth factors, such as FGF-b,
VEG-F, PDGF-AB and TGF-b, released from
Fig. 2 a Doubling times observed in the different cell lines
grown in the presence of FBS or PL 16, 17 and 18. Results are
presented as the means ± standard deviations (SD) obtained
from triplicates observed with FBS or PL 16, 17 and 18 for 6
passages. Thus, for PL cultures the means and SD of nine
observations are shown. *Statistically significant differences
between the two values (Student’s t test, p\ 0.05). b Represen-
tative evaluation of cell cycle analysis of various cell lines
carried out in the presence of FBS and PL 17. The average
values obtained in a triplicate analysis are presented for both
FBS and PL 17
Fig. 3 Expansion rates expressed as fold expansions of the
different cell lines grown in the presence of FBS or PL 16, 17
and 18. Results are presented as the means ± standard
deviations (SD) obtained from triplicates observed with FBS
or PL 16, 17 and 18. Thus, in the case of PL the means and SD of
nine observations are shown. *Statistically significant differ-
ences between the two values (Student’s t test, p\ 0.05)
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platelets during PL preparation process. Actually,
most of these factors, released in vivo upon PLT
activation, are known to play a critical role in the
wound healing process; therefore the properties of PL
in promoting in vitro cell growth is likely related to the
presence of growth factors released from PLTs after
freeze and thaw cycles. Three lots were specifically
tested for their capacity to support several established
tumor cell lines. These lots, named PL-16, PL-17 and
PL-18, were evaluated for the content of growth
factors (FGF-b, VEG-F, PDGF-AB, TGF-b) as pro-
duct quality indicators, and the value of each factor
was compared with the average values previously
detected for 20 PL preparations (Fig. 1). As depicted
in Fig. 1, the concentration of FGF-b, VEG-F, PDGF-
AB and TGF-b was over 70 % of the average values
(106 pg/ml ± 15 for FGF-b, 13.416 pg/ml ± 2.526
for VEGF-C, 55.547 pg/ml ± 7.673 for PDGF-AB
and 94.338 pg/ml ± 13.105 for TGF-b) and no
relevant variations were observed among the three
distinct lots. Also the MSCs-based ‘‘potency test’’ (see
section ‘‘Materials and methods’’) revealed that each
PL tested was able to support MSC growth within the
acceptability limits that have been stated for product
use in growth experiments.
Growth and proliferation
The experiments on human cell lines in vitro allow for
reproducing in laboratory the behaviour of human
cancer cells in vivo. Hence, these cells are often used
to assess the ability of drugs, immunity or biological
response modifiers to induce growth arrest, phenotyp-
ic and/or transcriptional changes with or without
differentiation, epigenetic regulations or expression of
new functional properties. In this field, the addition of
xenogeneic material to the cultures may alter in some
way the biologic response of these effectors due to the
xenogeneic activation or the cell over stimulation
(Balk et al. 1981).The growth promoting effect of PL
Fig. 4 A representative
example of phenotypic
analysis of various cell lines
carried out in the presence of
FBS and PL17. The average
values obtained in a
triplicate analysis are
presented for both FBS and
PL 17
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was evaluated with haematopoietic and epithelial cell
lines. Figure 2a shows the results in terms of doubling
time average obtained from each PL lot compared to a
single lot of commercial FBS. For each PL lot, three
replicates of all individual cell line were evaluated, for
a total of nine experiments, while three replicates of
each cell line were performed for FBS. The results
showed that FBS gave a faster replication rate for
haematopoietic cell lines (Fig. 2a), with an average of
doubling time 14 % higher then LP cultures, although
the difference was significantly higher only for Jurkat
and KG-1a (p\ 0.05), as assessed using Student’s
test. This observation was also associated with greater
percentage of cells in the S-phase of the cell cycle, as
depicted in Fig. 2b. An increase in G0/G1 phase of
analysed cell lines, ranging from 4.6 to 11.1 %, was
actually observed in the presence of PL. However,
even if these differences in G0/G1 phase were
consistently observed during cultures, they did not
reach statistical significance. The proliferation effect
of PL on these cell lines was also evaluated as fold
expansion comparing cell growth during passage 1–6
(Fig. 3). The results confirmed that PL supports
growth and expansion of all cell lines, although the
cells cultured in presence of PL experienced a less
massive proliferation compared to those grown on
FBS. In particular, for MCF-7 and HL-60 the differ-
ence persisted and was statistically significant also at
passage 6 (p\ 0.05), resulting, respectively, in a
fivefold instead of sevenfold expansion and in a
sixfold instead of eightfold expansion.
Phenotype and morphology
To analyse the lineage stability of cells cultured with
PL, we performed phenotypic analysis using a consti-
tutive marker for each cell line. In particular, we used
CD235a for K562, CD33 for HL60, CD3 for Jurkat,
Fig. 5 Microscope examination of various cell lines cultured in the presence of FBS or PL 17, showing similar cell characteristics at
morphologic analysis (9100 magnification)
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CD34 and CD45 for KG-1a, CD146 for HeLa and
CD29 for MCF-7. As depicted in Fig. 4, we found a
comparable percentage of viable specific marker-
expressing cells for each cell line cultured with either
FBS or PL, which confirmed the persistence of lineage
fidelity in all cultures at all passages (Fig. 4).
Figure 5 shows the morphologic aspect of cell lines
during culture in presence of FBS or PL (PL17). As
observed by microscopic examination, both K562 and
Jurkatt (lymphoblasts) and KG1-a and HL-60 (myelo-
blasts) showed a typical spherical shape and were
grown in suspension without attaching to the plate
surface in both culture conditions (LP or FBS). Also
for HeLa and MCF-7 (ephitelial cells) cells, which
showed a typical polygonal shape and were grown
attached to the plate, no differences were revealed
between FBS or PL driven cultures.
Functional assays
In order to evaluate the functional characteristics and
responsiveness of tumor cell lines grown with either
PL or FBS, we performed a more in depth analysis
with either drug sensitivity test and cytotoxicity assay
in vitro. Using KG-1a, HL-60 and Jurkat haematopoi-
etic cell lines only, we tested their sensitivity to
adriamycin exposure, using a drug dose range from
0.0025 to 0.5 lg/ml. Figure 6 shows that adriamycin
maintains a dose-related effect on growth of each cell
line in both FBS- and PL-supported cultures in a
representative experiment using PL17. In the case of
Fig. 6 A representative example of cell exposure to adriamycin
of KG-1a, HL-60 and Jurkat haematopoietic cell lines carried
out in the presence of FBS and PL 17. The average values
obtained in triplicate assays are presented for both FBS and PL
17 in a dose range from 0.0025 to 0.5 lg/ml
Fig. 7 Evaluation of NK cell-mediated cell lysis of K562 cells
grown in the presence of FBS or PL17 and PL18 at variable
effector/target ratios ranging from 20/1 to 2.5/1. Each data point
is presented as the mean ± standard deviation (SD) of three
different K562 cell lysis obtained culturing FBS- or PL-
supported cells with three different NK cell populations
obtained from three different healthy donors
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FBS cultures, a greater sensitivity to low doses of
adriamycin was observed and this might correlate with
the increased replication rate of these cells in presence
of FBS, as indicated by the increased S-phase in their
cultures. In fact, it seems that the presence of FBS
rendered these cells more sensitive to the drug, likely
altering the real capacity of these effectors to induce
growth arrest and cell death. Moreover, regarding this
aspect, it has been reported that primary leukemic cells
showed an S-phase ranging from 20 to 45 %, which is
the same range that we found in PL cultures, which
may more likely resemble the kinetic behaviour of
these primary cells (Ishiyama et al. 1994). However, a
proper dose–response curve was also observed for
cells cultured in PL, indicating a preserved cell
sensitivity to the drug, with differences that did not
reach statistical significance at any dose-point, except
for HL-60 at 0.005 and 0.01 lg/ml (p\ 0.05).
Finally, as K562 is a cell line susceptible to lysis by
NK effectors, we tested the ability of IL-2 activated NK
cells to lyse K562 target cells cultured with FBS or PL
to verify whether the presence of PL in culture medium
could influence sensitivity of K562 to NK killing. Three
distinct NK cell populations were generated by cultur-
ing PBMC from three healthy donors in presence of
high dose IL-2 and their lytic potential was tested
against K562 cultivated, respectively, with FBS or PL
(lots PL17 and PL18). NK effector cells were co-
cultured with FBS-K562 or LP-K562 target cells for
90 min at an E/T cell ratio ranging between 20/1 and
2.5/1. All the three NK cells showed an high lytic
activity against both FBS or LP driven K562 targets
with a percentage of specific lysis between 80 and 20 %
according to the E/T ratios. These findings confirmed
that PL-supported K562 cells retained sensitivity to NK
cell-mediated lysis with a proper dose–response curve
comparable, at any E/T ratios, to the curve obtained
with FBS-cultured K562 cells (Fig. 7).
Conclusion
The efforts to find a substitute to replace FBS has
become a relevant goal in the field of cell and tissue
culture since the use of FBS may present several
disadvantages, both for the ethical concerns about its
collection and production, and for the requirement of
safe, defined and animal-free culture conditions for
experimental cultures and cell therapy use (Bernardo
et al. 2007; Gstraunthaler 2003; Jochems et al. 2002;
Sundin et al. 2007). Moreover, the replacement of
FBS, which can often display high batch-to-batch
variability, would lead to a better quality and repro-
ducibility of experimental data (Balls and Morton
2010; Brunner et al. 2010). For these reasons, many
human alternatives to animal serum have been tested
in the last decades, including growth factors, human
serum and plasma, tissue extract and PL. (Ferro et al.
2012; Gstraunthaler 2003; Hankey et al. 2001;
Kocaoemer et al. 2007; Lin et al. 2005; Morimoto
et al. 2011; Stute et al. 2004). PL can be obtained from
outdated donor PLTs and contains a wide series of
growth factors. The stimulatory effect of PL for
in vitro cell propagation has been already proven by
several reports, that, for the most part, have been
conducted to find a human FBS replacement for
clinical-grade expansion of MSCs. Nevertheless, the
development of cellular therapeutics requires the use
of standardized products for cell culture with the
mandatory avoidance of animal-derived components
and the compliance with GMP (Fekete et al. 2012).
Thus, in view of the rapidly increasing applications of
MSCs, as previously showed, we have set up a clinical
grade protocol to produce a standardized and safe PL
for clinical-grade cell expansion (Iudicone et al.
2014). In the present study, we analyzed the ability
of PL to support the normal rate of growth and
expansion of established haematopoietic and epithe-
lial cancer cell lines in comparison with FBS. We
tested three different lots of PL for the content of
growth factors and the ability to sustain MSCs growth.
LP was added to culture medium at the same
concentration as used for the competitor FBS. The
growth promoting effect of PL was evaluated in terms
of doubling time and fold expansion during passage
1–6. The results confirmed that PL supports growth
and expansion of all cell lines, although the cells
cultured in presence of PL experienced a less massive
proliferation compared to those grown on FBS.
However, we found no differences in terms of cell
morphology, phenotype and sensitivity to adriamycin
and to NK cell-mediated lysis. In conclusion, we have
demonstrated that human PL (now trademarked as
Mesengen and produced by Futura Re-Life, Rome,
Italy) is able to support growth and propagation of
human cell lines without altering their morphologic,
phenotypic and functional characteristics. PL can be
produced at relatively low cost, without ethical issues
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and safety concerns, and can offer substantial advan-
tages for various applications in the field of cell and
tissue culture, both from a perspective of performance,
process standardization, ethicality and product safety.
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